Moderna's Covid-19 vaccine would not have scaled without Ginkgo Bioworks. Reshma Shetty, co-founder and COO of Ginkgo – slated to go public via SPAC acquisition at a reported $15 billion valuation – explains how biotech innovation can build a better future now. Ginkgo's platform already serves industries from food and agriculture, to materials, to healthcare. Shetty acknowledges that engineering genes is a high stakes pursuit, and says Ginkgo is trying to pair the ambition of Silicon Valley with a "higher level of care" than consumer tech companies like social media have demonstrated. The key, Shetty says, is creating an unstable equilibrium – propelling progress but not at the expense of principles.Read a transcript of this interview at:&nbsp;<a href="https://mastersofscale.com/" rel="noopener noreferrer" target="_blank">mastersofscale.com</a>Subscribe to the Masters of Scale weekly newsletter at&nbsp;<a href="http://eepurl.com/dlirtX" rel="noopener noreferrer" target="_blank">http://eepurl.com/dlirtX</a>

Podurama

Home

Trending

Personal

Your Podcasts

New Episodes

My Files

Favourite Episodes

Tags (Folders)

Recently Played

Bookmarks

Followed Playlists

Rapid Response: The promise and peril of engineering biology, w/Ginkgo Bioworks Reshma Shetty

WaitWhat